Surovatamig + R-CHOP + R-CVP + BR
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Untreated Follicular Lymphoma
Conditions
Untreated Follicular Lymphoma
Trial Timeline
Aug 7, 2024 → Nov 26, 2031
NCT ID
NCT06549595About Surovatamig + R-CHOP + R-CVP + BR
Surovatamig + R-CHOP + R-CVP + BR is a phase 3 stage product being developed by AstraZeneca for Untreated Follicular Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06549595. Target conditions include Untreated Follicular Lymphoma.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06549595 | Phase 3 | Recruiting |
Competing Products
15 competing products in Untreated Follicular Lymphoma